# Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting

> **NCT05590923** · PHASE4 · TERMINATED · sponsor: **The Guthrie Clinic** · enrollment: 24 (actual)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** OLA group: Olanzapine
- **DRUG:** DEX group: Dexamethasone

## Key facts

- **NCT ID:** NCT05590923
- **Lead sponsor:** The Guthrie Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-07
- **Primary completion:** 2025-07-08
- **Final completion:** 2025-07-08
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Study stopped due to lower than expected accrual.
- **Last updated:** 2025-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05590923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05590923, "Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05590923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*